NCT05083936Unknown不适用
Prospective Comparison of 18F-FDG and 18F-FET PET for Response Evaluation in Patients With Primary Central Nervous System Lymphoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Change of target to background ratio between baseline, mid-therapy and end-of treatment PET in patients with primary central nervous system lymphoma
研究概览
简要总结
The overall goal of this imaging trial is to prospectively compare the usefulness of 18F-FDG PET and 18F-FET PET in evaluating treatment response and predicting prognosis in patients with central nervous system lymphoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •In order to be eligible for participation in this trial, the subject must:
- •Be ≥ 19 years of age.
- •Patients diagnosed with central nervous system lymphoma by surgery/biopsy or suspected of central nervous system lymphoma by anatomical imaging examination such as MRI.
- •Patients who have results or are planning to examine 18F-FDG PET in the above patients.
排除标准
- •The subject must be excluded from participating in the trial if the subject fulfil any single criteria described below:
- •Pediatric and adolescent patients under 19 years of age.
- •The patient is pregnant, is attempting to become pregnant, or is nursing (breast-feeding) to children.
- •Patients with diagnosed or suspected lymphoma lesions in organs other than the cetral nervous system.
- •Based on the investigator's judgement, if the patient makes it impossible to collect complete data for a clinical trial due to personal or other reasons.
- •Patients who cannot stably have PET/CT due to claustrophobia, dyskinesia, anxiety disorder, seizure, etc.
- •Based on the investigator's judgement, if the patient has a serious and/or uncontrolled and/or unstable medical disease (e.g., congestive heart failure, acute myocardial infarction, severe lung disease, chronic renal disease or chronic liver disease, etc.)
研究组 & 干预措施
[18F]FET PET
Experimental
干预措施: [18F]FET (Drug)
结局指标
主要结局
Change of target to background ratio between baseline, mid-therapy and end-of treatment PET in patients with primary central nervous system lymphoma
时间窗: 20-40 minutes post injection
次要结局
- 1.5 year progression free survival(18months)
研究者
Minyoung Oh
Assistant professor
Asan Medical Center
研究点 (1)
Loading locations...
相似试验
已完成
不适用
18F-FDG Tomography and Labeled Leukocyte ScintigraphyMalignant Otitis ExternaNCT05994768Central Hospital, Nancy, France18
尚未招募
不适用
Comparison Study Between PET/CT and Whole-Body Diffusion Weighted MRI in the Detection of Distant MalignanciesDistant MetastasisNCT06205901Sohag University50
已完成
不适用
Comparison of 18F FDG PET/CT TO PET MRIAny Condition With a Clinical Indication for PET/CT ExamNCT01986985GE Healthcare58
进行中（未招募）
不适用
FDG-PET/CT for Simulation and Radiation Treatment Planning of Early Breast CancerBreast NeoplasmNCT01432002University Hospital, Geneva60
已完成
早期 1 期
18F-FLT Positron Emission Tomography and Diffusion-Weighted Magnetic Resonance Imaging in Planning Surgery and Radiation Therapy and Measuring Response in Patients With Newly Diagnosed Ewing SarcomaAdult Supratentorial Primitive Neuroectodermal Tumor (PNET)Ewing Sarcoma of BoneExtraosseous Ewing SarcomaLocalized Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorMetastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorUntreated Childhood Supratentorial Primitive Neuroectodermal TumorNCT01825902Mayo Clinic1